Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantCompleted
NCT05477108Phase 1Updated Aug 28, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
United States
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With AsthmaCompleted
NCT06245551Phase 3Updated Aug 27, 2025
Sponsor: AstraZeneca
Asthma, Exercise-Induced
Russia
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)Completed
NCT06744374N/AUpdated Aug 27, 2025
Sponsor: AstraZeneca
Pulmonary Disease, Chronic Obstructive
United States
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting
NCT02969798NAUpdated Aug 27, 2025
Sponsor: The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2 · Impaired Glucose Tolerance (IGT) · Impaired Fasting Glucose (IFG)
United States
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%Completed
NCT04986202Phase 2, Phase 3Updated Aug 27, 2025
Sponsor: AstraZeneca
Heart Failure With Preserved Ejection Fraction
United States, Australia, Belgium, Brazil, Bulgaria +13 more
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDCompleted
NCT06075095Phase 3Updated Aug 27, 2025
Sponsor: AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
United States, Argentina, Bulgaria, Canada, Hungary +9 more
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in EgyptNot Yet Recruiting
NCT07144514N/AUpdated Aug 27, 2025
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's DiseaseCompleted
NCT06053424Phase 1Updated Aug 27, 2025
Sponsor: AstraZeneca
Crohn's Disease
Sweden
Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.Completed
NCT06514157Phase 1Updated Aug 26, 2025
Sponsor: AstraZeneca
Healthy Volunteer
China
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic RadiotherapyActive Not Recruiting
NCT05796089Phase 2Updated Aug 26, 2025
Sponsor: Trans Tasman Radiation Oncology Group
Extensive-Stage Small-Cell Lung Cancer
Australia
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruiting
NCT05582538Phase 2Updated Aug 24, 2025
Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
Triple Negative Breast Cancer Metastatic
Italy
Effect of Benralizumab in Atopic DermatitisCompleted
NCT03563066Phase 2Updated Aug 22, 2025
Sponsor: McMaster University
Dermatitis, Atopic · Dermatitis · Eczema · Skin Diseases
Canada
A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantCompleted
NCT05569421Phase 1Updated Aug 22, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
United States
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsCompleted
NCT04053634Phase 3Updated Aug 19, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
United States, Argentina, Australia, Austria, Belgium +25 more
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health ServiceCompleted
NCT06261567N/AUpdated Aug 19, 2025
Sponsor: AstraZeneca
Asthma
United Kingdom
Clinico-biological Data Collection Study of Metastatic Breast CancerActive Not Recruiting
NCT03958136NAUpdated Aug 17, 2025
Sponsor: Institut Cancerologie de l'Ouest
Breast Cancer
France
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompleted
NCT03638141Phase 2Updated Aug 17, 2025
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intermediate Stage of Hepatocellular Carcinoma · Hepatocellular Carcinoma
United States
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)Completed
NCT07103642N/AUpdated Aug 15, 2025
Sponsor: AstraZeneca
Pulmonary Disease, Chronic Obstructive
United States
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesCompleted
NCT03739931Phase 1Updated Aug 15, 2025
Sponsor: ModernaTX, Inc.
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma · Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
United States, Australia, Israel
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a SpacerWithdrawn
NCT06340581Phase 1Updated Aug 15, 2025
Sponsor: AstraZeneca
Healthy
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)Terminated
NCT05516498Phase 2Updated Aug 15, 2025
Sponsor: AstraZeneca
Liver Cirrhosis
United States, Australia, Austria, Belgium, China +10 more
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19Completed
NCT06057064Phase 2Updated Aug 15, 2025
Sponsor: AstraZeneca
COVID-19, SARS-CoV-2
Russia
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a SpacerCompleted
NCT06297668Phase 1Updated Aug 13, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
Germany
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.Not Yet Recruiting
NCT05888857Phase 2Updated Aug 13, 2025
Sponsor: Institut Bergonié
Advanced Solid Tumor
France
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsCompleted
NCT01078662Phase 2Updated Aug 13, 2025
Sponsor: AstraZeneca
Ovarian · Breast · Prostate · Pancreatic
United States, Australia, Germany, Israel, Spain +1 more

Previous page Next page